perflexane

Trade name: Imagent

Small moleculeapproved

Approved

May 31, 2002

Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure. Commercially available contrast media are gas-filled microbubbles that are administered intravenously to the systemic circulation. Microbubbles have a high degree of echogenicity. There is a great difference in echogenicity between the gas in the microbubbles and the soft tissue surroundings of the body. Thus, ultrasonic imaging using microbubble contrast agents enhances the ultrasound backscatter, (reflection) of the ultrasound waves, to produce a sonogram with increased contrast due to the high echogenicity difference. Contrast-enhanced ultrasound can be used to image blood perfusion in organs, measure blood flow rate in the heart and other organs, and for other applications. — Wikipedia

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1990s

  1. Aug 13, 1993

    Alliance Pharmaceutical Corp. — First NDA Organization

  2. Aug 13, 1993

    Alliance Pharmaceutical Corp. — NDA Organization

2000s

  1. May 31, 2002

    Earliest FDA Approval

  2. May 31, 2002

    Vesselon Spv Llc — NDA Secondary Org

Indications

Mechanism of action

Combination products

Approval history

  • approvedMay 31, 2002

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
Alliance Pharmaceutical Corp.For profitNDAAug 13, 1993
Vesselon Spv LlcFor profitNDA2May 31, 2002